Significance of the Phase III FLAURA Study in EGFR+ NSCLC

The primary end point of overall survival was not met in the phase 3 SAPPHIRE study of sitravatinib plus nivolumab in patients with advanced non-squamous non–small cell lung cancer.

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the PACIFIC and PACIFIC-R studies of durvalumab in patients with unresectable stage III non–small cell lung cancer.

Community physician Jason Williams, MD, DABR, talks to academic oncologist George R. Simon, MD, FACO, FCCP, for an episode of Targeted Talks.

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the considerations for treating a patient diagnosed with stage IIB lung adenocarcinoma.

Positive findings from the FLAURA2 study add to the body of evidence supporting treatment with osimertinib for patients with EGFRm non–small cell lung cancer.